CANNABIDIOL (CBD), Pre-Review Report, Agenda Item 5.2 Expert Committee on Drug Dependence Thirty-ninth Meeting, Geneva, 6-10 November 2017 39th ECDD (2017) Agenda item 5.2 Cannabidiol (CBD) Contents Acknowledgements .................................................................................................................. 4 Summary ................................................................................................................................... 5 1. Substance identification ........................................................................................................ 6 A. International Nonproprietary Name (INN) .......................................................................... 6 B. Chemical Abstract Service (CAS) Registry Number .............................................................. 6 C. Other Chemical Names .......................................................................................................... 6 D. Trade Names .......................................................................................................................... 6 E. Street Names .......................................................................................................................... 6 F. Physical Appearance .............................................................................................................. 6 G. WHO Review History ............................................................................................................. 6 2. Chemistry ............................................................................................................................... 6 A. Chemical Name ...................................................................................................................... 6 B. Chemical Structure ................................................................................................................. 7 C. Stereoisomers ......................................................................................................................... 7 D. Methods and Ease of Illicit Manufacturing ............................................................................ 7 E. Chemical Properties ............................................................................................................... 9 F. Identification and Analysis ..................................................................................................... 9 3. Ease of [...]
Lire la suiteBibliographie : Interactions et antagonisme THC - CBD Docteur Christian SUEUR, GRECC, mars 2020. Les interactions entre le THC et le CBD sur le système endocannabinoide, quant aux effets psychotomimetic (production de "symptomes psychotiques") sont opposés : là où le THC produit préférentiellement de l'anxiété, et des effets "psychotisants", le CBD est plutôt anxiolytique et "antipsychotique". Ces deux phytocannabinoïdes sont "antagonistes", et contribuent, parmi d'autres inter-relations entre les phytocannabinoïdes, les terpènes et les flavonoïdes composant le cannabis, aux "effets d'entourage" fondamentaux, tout autant quant à la production "d'effets indésirables" et de risques pour la santé mentale du consommateur, que dans le cadre de [...]
Lire la suiteCannabis for pediatric epilepsy : protocol for a living systematic review Jesse Elliott, Deirdre DeJean, Tammy Clifford, Doug Coyle, Beth Potter, Becky Skidmore, Christine Alexander, Alexander E. Repetski, Bláthnaid McCoy and George A. Wells Systematic Reviews, 2018, 7, 95 doi : 10.1186/s13643-018-0761-2 Abstract Background : Pediatric epilepsy, including treatment-resistant forms, has a major effect on the quality of life, morbidity, and mortality of affected children. Interest has been growing in the use of medical cannabis as a treatment for pediatric epilepsy, yet there has been no comprehensive review of the benefits and harms of cannabis use in this population. In this systematic review, we will [...]
Lire la suiteBibliographie : Cannabinoïdes et Epilepsie Docteur Christian SUEUR, GRECC, version actualisée, mars 2020
Lire la suiteCannabis as Medicine: How CBD (Cannabidiol) Benefits the Brain and Nervous System Audrey Lefebvre wakeup-world.com/2016/03/20/cannabis-as-medicine-how-cbd-cannabidiol-benefits-the-human-brainand-nervous-system/ Cannabidiol (CBD) is an active cannabinoid found in cannabis which, unlike THC (tetrahydro-cannabinol), does not produce a psychoactive effect in the brain. For this reason, CBD has become a primary focus of medicinal cannabis studies. CBD has been found to have a wide range of benefits, including lowering blood sugar levels, promoting bone growth, and importantly, protecting the human brain and nervous system from degeneration. How CBD Protects the Nervous System The nervous system is comprised of two main parts: the peripheral nervous system, which includes the nerves and ganglia on [...]
Lire la suiteTherapeutic Satisfaction and Subjective Effects of Different Strains of Pharmaceutical-Grade Cannabis Tibor M. Brunt, Marianne van Genugten, Kathrin Honer-Snoeken, Marco J. van de Velde, and Raymond J.M. Niesink Journal of Clinical Psychopharmacoly, 2014, 34, 344Y349 Doi : 10.1097/JCP.0000000000000129 Abstract : In The Netherlands, pharmaceutical-grade cultivated cannabis is distributed for medicinal purposes as commissioned by the Ministry of Health. Few studies have thus far described its therapeutic efficacy or subjective (adverse) effects in patients. The aims of this study are to assess the therapeutic satisfaction within a group of patients using prescribed pharmaceutical-grade cannabis and to compare the subjective effects among the available strains with special [...]
Lire la suiteOlivier Véran pour l’extension de l’expérimentation du cannabis médical à la Polynésie française Newsweed, 18 février 2020 Aurélien BERNARD Olivier Véran, nommé ministre de la Santé ce week-end en remplacement d’Agnès Buzyn, n’aura pas besoin d’être mis dans le bain pour reprendre le dossier du cannabis thérapeutique en France. Ce dernier a en effet porté le projet d’expérimentation du cannabis médical et est à l’origine du passage de son amendement dans la loi de Finances 2020. En réponse à une question de son ancien collègue député polynésien, Moetai Brotherson, qui l’interrogeait sur la possibilité d’étendre l’expérimentation métropolitaine du cannabis médical à la Polynésie française, [...]
Lire la suiteCannabinoid and Terpenoid Doses are Associated with Adult ADHD Status of Medical Cannabis Patients Jeffrey Y. Hergenrather, Joshua Aviram, Yelena Vysotski, Salvatore Campisi-Pinto, Gil M. Lewitus and David Meiri. Rambam Maimonides Medical Journal, 2020, 11, (1), e0001 Doi : 10.5041/RMMJ.10384 Methods : Participants were adult patients licensed for medical cannabis (MC) treatment who also reported a diagnosis of ADHD by a physician. Data on demographics, ADHD, sleep, and anxiety were collected using self-report questionnaires. Data collected on MC treatment included administration route, cultivator, cultivar name, and monthly dose. Comparison statistics were used to evaluate differences in reported parameters between low (20–30 g, n=18) and [...]
Lire la suiteIACM-Bulletin du 18 Février 2020 IACM: Conférences en novembre 2020 à Mexico et en octobre 2021 à Bâle Science/Homme: Un nombre croissant de patients atteints de maladies rhumatismales aux États-Unis consomment du cannabis Science/Homme: L’arrêt de l'utilisation du CBD ne provoque pas de symptômes de sevrage Science/Homme: Après l'adoption des lois sur le cannabis médical aux États-Unis, l'indemnisation des accidents du travail a été réduite Science/Homme: La consommation de cannabis est associée à une réduction des symptômes du TDAH En bref Un coup d'œil sur le passé IACM: Conférences en novembre [...]
Lire la suiteThe Psychiatric Consequences of Cannabinoids Joao P. De Aquino, Mohamed Sherif, Rajiv Radhakrishnan, John D. Cahill, Mohini Ranganathan and Deepak C. D’Souza Clinical Therapeutics, 2018, 40, (9), 14481456 Doi : 10.1016/j.clinthera.2018.03.013 ABSTRACT With rising rates of cannabis use in the general population and an increasing number of US states legalizing both recreational and medical cannabis use, it is important to be informed about the adverse consequences of cannabinoids. This Commentary provides an overview of the psychiatric effects of plant-based and synthetic cannabinoids, differentiating acute effects from effects associated with persistent use. Cannabinoids produce multiphasic and dose dependent effects on anxiety, mood, and perception, in addition [...]
Lire la suite